MARKET

NURO

NURO

Neurometrix Inc
NASDAQ
1.910
-0.010
-0.52%
After Hours: 1.970 +0.06 +3.14% 19:35 02/03 EST
OPEN
1.920
PREV CLOSE
1.920
HIGH
1.970
LOW
1.890
VOLUME
29.29K
TURNOVER
0
52 WEEK HIGH
5.89
52 WEEK LOW
1.326
MARKET CAP
14.82M
P/E (TTM)
-2.7924
1D
5D
1M
3M
1Y
5Y
NeuroMetrix Received Decision To Grant European Patent Titled 'TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION USING NOVEL UNBALANCED BIPHASIC WAVEFORM AND NOVEL ELECTRODE ARRANGEMENT'
Benzinga · 01/25 18:15
NeuroMetrix Announces Launch Of DPNCheck 2.0, Its Fast, Accurate, Quantitative Screening Test For Peripheral Neuropathy
Benzinga · 01/23 14:16
Gladstone Commercial, Prenetics Global, Xunlei among premarket losers' pack
Seeking Alpha · 01/11 13:33
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 01/11 13:05
NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting
WOBURN, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will introduce Quell Fibromyalgia at the American College of Rheumatology Annual Meeting, ACR Convergence 2022, on November 12 – 14 in Philadelphia, Pennsylvania. Quell Fibro...
GlobeNewswire · 11/08/2022 14:00
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 11/08/2022 12:11
Why TripAdvisor Shares Are Trading Sharply Lower; Here Are 29 Stocks Moving Premarket
Benzinga · 11/08/2022 11:08
NeuroMetrix Announces Strategic Launch Of Quell Fibromyalgia
Benzinga · 11/03/2022 13:04
More
About NURO
NeuroMetrix, Inc. develops and commercializes health care products that utilize non-invasive neurostimulation. The Company is engaged in the designing, building and marketing of medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. It has two principal product categories, which includes point-of-care neuropathy diagnostic tests and wearable neurostimulation devices. Its products include DPNCheck, Quell and ADVANCE System. DPNCheck is a quantitative nerve conduction test that is used to evaluate peripheral neuropathies, such as Diabetic peripheral neuropathy (DPN). Quell a wearable device for symptomatic relief and management of chronic pain. ADVANCE System is a platform for the performance of nerve conduction studies. DPNCheck customers include managed care organizations, endocrinologists, podiatrists and primary care physicians. ADVANCE System customers include occupational health, primary care, internal medicine and many others.

Webull offers kinds of Neurometrix Inc stock information, including NASDAQ:NURO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NURO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NURO stock methods without spending real money on the virtual paper trading platform.